NCT06626945Completed
AZAHAR Study To Describe Anifrolumab in a Real-World Setting
AZAHAR Study. Observational Retrospective Study To Describe Characteristics And Clinical Outcomes of Patients With Systemic Lupus Erythematosus Initiating Saphnelo (Anifrolumab) in a Real-World Setting
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
AZAHAR is an observational retrospective and longitudinal study with adults patients with SLE who initiated treatment with anifrolumab from June 1, 2023 to May 31, 2024. The overall objective is to describe the characteristics and clinical outcomes of patients with SLE that initiated anifrolumab during its first year of commercialization in Spain.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 152 (actual)
- First submitted
- 26 Sept 2024
- Start date
- 3 Feb 2025
- Primary completion date
- 5 Jun 2025
- Lead sponsor
- AstraZeneca
- Diseases
- Lupus (SLE)
- NCT number
- NCT06626945
What you commit to
- Study type: Observational
- Participants enrolled: 152
- From 3 Feb 2025 to the primary completion date, 5 Jun 2025
- 13 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or previous exposure to anifrolumab as part of a clinical trial or Early Access Program (EAP).
Who the study is looking for
- Fulfilled the 2019 EULAR/ACR criteria for SLE at the date of anifrolumab initiation.
- Aged 18 years or older at the date of anifrolumab initiation.
- Have initiated anifrolumab between June 1st, 2023, and May 31st, 2024
- Have at least 12 months of medical history prior to anifrolumab initiation.
Age in the registry: 18 years to 130 years · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Granada | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Jaén | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | León | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | L'Hospitalet de Llobregat | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Málaga | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Mérida | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Móstoles | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Murcia | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Seville | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Toledo | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Valladolid | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.